Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
City of Hope, Duarte, California Cleveland Clinic, Cleveland, Ohio SCRI Oncology Partners - PPDS, Nashville, Tennessee START Mountain Region, West Valley City, Utah Canada
McGill University Health Centre (MUHC) - The Montreal, Québec, Canada Princess Margaret Cancer Centre, Toronto, Ontario